Percutaneous Left Atrial Appendage Occlusion: An Emerging Option in Patients with Atrial Fibrillation at High Risk of Bleeding

被引:8
作者
Cimmino, Giovanni [1 ,2 ]
Loffredo, Francesco S. [1 ,2 ,3 ]
Gallinoro, Emanuele [1 ,4 ]
Prozzo, Dario [1 ]
Fabiani, Dario [1 ]
Cante, Luigi [1 ,2 ]
Salerno, Gemma [2 ]
Cappelli Bigazzi, Maurizio [2 ]
Golino, Paolo [1 ,2 ]
机构
[1] Univ Campania Luigi Vanvitelli, Dept Translat Med Sci, I-80131 Naples, Italy
[2] Monaldi Hosp, Vanvitelli Cardiol Unit, I-80131 Naples, Italy
[3] Int Ctr Genet Engn & Biotechnol, Mol Cardiol, I-34149 Trieste, Italy
[4] OLV Clin, Cardiovasc Ctr Aalst, B-9300 Aalst, Belgium
来源
MEDICINA-LITHUANIA | 2021年 / 57卷 / 05期
关键词
atrial fibrillation; cardioembolism; stroke prevention; bleeding risk; left atrial appendage occlusion; AMPLATZER AMULET DEVICE; LONG-TERM WARFARIN; STROKE PREVENTION; CONSENSUS STATEMENT; ORAL ANTICOAGULANTS; CLOSURE; OUTCOMES; SAFETY; MECHANISMS; THROMBUS;
D O I
10.3390/medicina57050444
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atrial fibrillation (AF) is a common cardiac arrhythmia with an estimated prevalence of 1% in the general population. It is associated with an increased risk of ischemic stroke, silent cerebral ischemia, and cognitive impairment. Due to the blood flow stasis and morphology, thrombus formation occurs mainly in the left atrial appendage (LAA), particularly in the setting of nonvalvular AF (NVAF). Previous studies have shown that >90% of emboli related to NVAF originate from the LAA, thus prevention of systemic cardioembolism is indicated. According to the current guidelines, anticoagulant therapy with direct oral anticoagulants (DOACs) or vitamin K antagonists (VKAs), represents the standard of care in AF patients, in order to prevent ischemic stroke and peripheral embolization. Although these drugs are widely used and DOACs have shown, compared to VKAs, non-inferiority for stroke prevention with significantly fewer bleeding complications, some issues remain a matter of debate, including contraindications, side effects, and adherence. An increasing number of patients, indeed, because of high bleeding risk or after experiencing life-threatening bleedings, must take anticoagulants with extreme caution if not contraindicated. While surgical closure or exclusion of LAA has been historically used in patients with AF with contradictory results, in the recent years, a novel procedure has emerged to prevent the cardioembolic stroke in these patients: The percutaneous left atrial appendage occlusion (LAAO). Different devices have been developed in recent years, though not all of them are approved in Europe and some are still under clinical investigation. Currently available devices have shown a significant decrease in bleeding risk while maintaining efficacy in preventing thromboembolism. The procedure can be performed percutaneously through the femoral vein access, under general anesthesia. A transseptal puncture is required to access left atrium and is guided by transesophageal echocardiography (TEE). Evidence from the current literature indicates that percutaneous LAAO represents a safe alternative for those patients with contraindications for long-term oral anticoagulation. This review summarizes scientific evidences regarding LAAO for stroke prevention including clinical indications and an adequate patient selection.
引用
收藏
页数:14
相关论文
共 76 条
  • [1] ABERG H, 1969, ACTA MED SCAND, V185, P373
  • [2] Left atrial appendage exclusion during mitral valve surgery and stroke in atrial fibrillation
    Abrich, Victor A.
    Narichania, Aalap D.
    Love, William T.
    Lanza, Louis A.
    Shen, Win-Kuang
    Sorajja, Dan
    [J]. JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2018, 53 (03) : 285 - 292
  • [3] Left atrial appendage: structure, function, and role in thromboembolism
    Al-Saady, NM
    Obel, OA
    Camm, AJ
    [J]. HEART, 1999, 82 (05) : 547 - 554
  • [4] Percutaneous Left Atrial Appendage Suture Ligation Using the LARIAT Device in Patients With Atrial Fibrillation Initial Clinical Experience
    Bartus, Krzysztof
    Han, Frederick T.
    Bednarek, Jacek
    Myc, Jacek
    Kapelak, Boguslaw
    Sadowski, Jerzy
    Lelakowski, Jacek
    Bartus, Stanislaw
    Yakubov, Steven J.
    Lee, Randall J.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (02) : 108 - 118
  • [5] European registry data on LAA closure: advancing the field of interventional stroke prevention
    Bergmann, Martin W.
    [J]. EUROINTERVENTION, 2018, 14 (02) : 135 - 138
  • [6] NOACs and atrial fibrillation: Incidence and predictors of left atrial thrombus in the real world
    Bertaglia, Emanuele
    Anselmino, Matteo
    Zorzi, Alessandro
    Russo, Vincenzo
    Toso, Elisabetta
    Peruzza, Francesco
    Rapacciuolo, Antonio
    Migliore, Federico
    Gaita, Fiorenzo
    Cucchini, Umberto
    De Divitiis, Marcello
    Iliceto, Sabino
    Stabile, Giuseppe
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 249 : 179 - 183
  • [7] Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation
    Blackshear, JL
    Odell, JA
    [J]. ANNALS OF THORACIC SURGERY, 1996, 61 (02) : 755 - 759
  • [8] Left atrial appendage occlusion for prevention of stroke in nonvalvular atrial fibrillation: a meta-analysis
    Bode, Weeranun D.
    Patel, Nikhil
    Gehi, Anil K.
    [J]. JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2015, 43 (01) : 79 - 89
  • [9] Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry
    Boersma, Lucas V. A.
    Schmidt, Boris
    Betts, Timothy R.
    Sievert, Horst
    Tamburino, Corrado
    Teiger, Emmanuel
    Pokushalov, Evgeny
    Kische, Stephan
    Schmitz, Thomas
    Stein, Kenneth M.
    Bergmann, MartinW.
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 (31) : 2465 - 2474
  • [10] Antithrombotic strategies after interventional left atrial appendage closure: an update
    Chen, Shaojie
    Weise, Felix K.
    Chun, K. R. Julian
    Schmidt, Boris
    [J]. EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2018, 16 (09) : 675 - 678